1. EFNS/MDS-ES Guidelines: Summary of the recommendations of the EFNS/ MDS-ES review on therapeutic management of Parkinson’s disease. Eur J Neurol. 2013 Jan; 20(1): 5-15.

2. Sławek J, Friedman A, Bogucki A, w wsp: Choroba Parkinsona i inne zaburzenia ruchowe- część 1. Via Medica 2011; 1; 175-212.

3. Whone AL, Watts RL, Stoessl AJ i wsp: REAL-PET Study Group. Slower progression of Parkinson’s disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003; 54: 93-101.

4. Gertel WH, Wolters E, Sampaio C i wsp: Pergolide versus levodopa monotherapy in early Parkinson’s disease patients: the PELMOPET study. Mov Disord 2006; 21: 343-353.

5. Holloway RG, Shoulson I, Fahn S i wsp: Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. The Parkinson Study Group. Arch Neurol 2004; 61: 1044-1053.

6. Kulisevsky J, Lopez-Villegas D, Garcia-Sanchez C i wsp: A sixmonth study of pergolide and levodopa in de novo Parkinson’s disease patients. Clin Neuropharmacol 1998; 21: 358-362.

7. Rinne UK, Bracco F, Chouza C i wsp: Cabergoline in the treatment of early Parkinson’s disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The KD 5009 Collaborative Study Group. Neurology 1997; 48: 363-368.

8. Koller WC, Hutton JT, Tolosa E i wsp: Immediate- release and controlled- release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/ Levodopa Study Group. Neurology 1999; 53: 1012-1019.

9. Goetz CG, Tanner CM, Shannon KM I wsp: Controlled-release carbidopa/levodopa (CR4- Sinemet) in Parkinson’s disease patients with and without motor fluctuations. Neurology 1988; 38: 1143-1146.

10. Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 1989; 321: 1364-1371.

11. Myllyla VV, Sotaniemi KA, Vourinen JA i wsp: Selegiline as initial treatment In de novo parkinsonian patients. Neurology 1992; 42: 339-343.

12. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 2002; 59: 1937-1943.

13. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004; 61: 561-566.

14. Teravainen H. Selegiline in Parkinson’s disease. Acta Neurol Scand 1990; 81: 333-336.

15. Allain H, Pollak P, Neukirch HC. Symptomatic effect of Selegiline in de novo Parkinsonian patients. The Grench Selegiline Multicenter Trial. Mov Disord 1993; 8 (Suppl.1): 536-540.

16. Palhagen S, Heinonen EH, Hagglund J i wsp: Selegiline delays the onset of disability in de novo parkinsonian patients. Swedish Parkinson Study Group. Neurology 1998; 51: 520-525.

17. Olanow CW, Rascol O, Hauser R I wsp: A doubleblind, delayed-start trial of rasagiline in Parkinson’s disease. N Engl J Med 2009; 361: 1268-1278.

18. Begamasco B, Frattola L, Muratorio A i wsp: Alpha-dihydroergocryptine in the treatment of de novo parkinsonian patients: results of a multicentre, randomized, double-blind, placebocontrolled study. Acta Neurol Scand 2000; 101: 372-380.real

19. Barone P, Bravi D, Bermejo-Pareja F I wsp: Pergolide monotherapy in the treatment of early PD: a randomized, controlled study. Pergolide Monotherapy Study Group. Neurology 1999; 53: 573-579.

20. Shannon KM, Bennett JP Jr, Friedman HJ. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson’s diseae. The PramipexoleStudy Group. Neurology 1997; 49: 724-728.

21. Adler CH, Sethi KD, Hauser RA i wsp: Ropinirole for the treatment of early Parkinson’s disease. The Ropinirole Study Group. Neurology 1997; 49: 393-399.

22. Rascol O, Dubois B, Caldas AC i wsp: Early piribedil monotherapy of Parkinson’s disease: a planned seven-month report of the REGAIN-study. The Parkinson REGAIN Study Group. Mov Disord 2006; 21: 2110-2115.

23. Parkinson Study Group. A controlled trial of rotigotine monotherapy in early Parkinson’s disease. Arch Neurol 2003; 60: 1721-1728.

24. RInne UK. Lisuride, a dopamine agonist in the treatment of early Parkinson’s disease. Neurology 1989; 39: 336-339.

25. Riopelle RJ. Bromocriptine and the clinical spectrum of Parkinson’s disease. Can J Neurol Sci 1987; 14: 455-459.

26. RInne UK, Bracco F, Chouza C i wsp: Early treatment of Parkinson’s disease with cabergoline delays the onset of motor complications. Results of a doubleblind levodopa controlled trial. The PKD 5009 Study Group. Drugs 1998; 55 (Suppl.1): 23-30.

27. Parkes JD, Baxter RC, Marsde CD, Rees JE. Comparative trial of benzhexol, amantadine and levodopa in the treatment of Parkinson’s disease. J Neurol Neurosurg Psychiatry 1974; 37: 422-426.

28. Cooper JA, Sagar HJ, Doherty SM i wsp: Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson’s disease. A follow-up study of untreated patients. Brain 1992; 115(Pt6): 1701-1725.

29. Levine CB, Fahrbach KR, Siderowf AD i wsp: Diagnosis and treatment of Parkinson’s disease: a systematic review of the literature. Evid Rep Technol Assess (Summ) 2003; 57: 1-4.

30. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson’s disease (2001): treatment guidelines. Neurology 2001; 56: S1-S88.

31. Jankovic J. Motor fluctuations and dyskinesias in Parkinson’s disease: clinical manifestations. Mov Disord 2005; 20 (Suppl. 11): S11-S16.

32. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group. JAMA 2000; 284: 1931-1938.

33. Hauser RA, Rascol O, Korczyn AS i wsp: Ten-year follow-up of Parkinson’s disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord 2007; 22: 2409-2417.

34. Watts RL, Lyons KW, Pahwa R i wsp: Onset of dyskinesias with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson’s disease. Mov Disord 2010; 25: 858-866.

35. Savery F. Amantadine and a fixed combination of levodopa and carbidopa in the treatment of Parkinson’s disease. Dis Nerv Syst 1977; 38: 605-608.

36. Katzenschlager R, Sampaio C, Costa J, Lees A. Anticholinergics for symptomatic management of Parkinson’s disease. Cochrane Database Syst Rev 2003; 2: CD003735.

37. Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson’s disease. Mov Disord 2005; 20, 1255-1263.

38. Aarsland D, Andersen K, Larsen JP i wsp: Prevalence and characteristics of dementia in Parkinson disease: and 8-year prospective study. Arch neurol 2003; 60: 387-392.

39. Emre M, Aarsland D, Albanese A i wsp: Rivastigmine for dementia associated ith Parkinson’s disease. N Engl J Med 2004; 351: 2509-2518.

40. Leroi I, Brandt J, Reich SG i wsp: Randomized placebo-controlled trial of donepezil In cognitive impairment In Parkinson’s disease. Int J Geriatr Psychiatry 2004; 19: 1-4.

41. Litvinenko IV, Odinak MM, Mogil’naya VI i wsp: Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson’s disease (an open controlled trial). Neurosci Behav Physiol 2008; 38: 937-945.

42. Fenelon G, Mahieux F, Huon R i wsp: Hallucinations in Parkinson’s disease: prevalence, phenomenology and risk factors. Brain 2000; 123(Pt 4): 733-745.

43. Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. N Engl J Med 1999; 340: 757-763.

44. Morgante L, Epifanio A, Spina E I wsp: Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol 2004; 27: 153-156.

45. Bullock R, Cameron A. Rivastigmine for the treatment of dementia and visual hallucinations associated with parkinon’s disease: a case series. Curr med Res Opin 2002; 18: 258-264.

46. Cunnings JL. Depression an Parkinson’s disease: a review. Am J Psychiatry 1992; 149: 443-454.

47. Rektorova I, Rektor I, Bares M i wsp: Pramipexole and pergolide in the treatment of depression In Parkinson’s disease: national multicentre prospective randomized study. Eur J Neurol 2003; 10: 399-406.

48. Wientraub D, Morales KH, Moberg PJ I wsp: Antidepressant studies in Parkinson’s disease: a review and meta-analysis. Mov Disord 2005; 20: 1161-1169.

49. Jankovic J, Gilden JL, Hiner BC i wsp: Neurogenic orthostatic hypotension: a double- blind, placebo-controlled study with midodrine. Am J Med 1993; 95: 38-48.

50. Hoen MM. Levodopa-induced postural hypotension. Treatment with fludrocortisones. Arch Neurol 1975; 32: 50-51.

51. Benson GS, Raezer DM, Andrson JR i wsp: Effect of levodopa on urinary bladder. Urology 1976; 7: 24-28.

52. Winge K, Werdelin LM, Nielsen KK i wsp: Effects of dopaminergic treatment on bladder function in Parkinson’s disease. Neurourol Urodyn 2004; 23: 689-696.